Transient receptor potential V1 modulates neuroinflammation in Parkinson’s disease dementia: Molecular implications for electroacupuncture and rivastigmine

Document Type : Original Article

Authors

1 Department of Neurology, China Medical University Hospital, Taichung, Taiwan

2 Graduate Institute of Acupuncture Science, College of Chinese Medicine, China Medical University, Taichung, Taiwan

3 Everflourish Neuroscience and Brain Disease Center, China Medical University Hospital, Taichung, Taiwan

4 Department of Chinese Medicine, China Medical University Hospital, Taichung, Taiwan

5 College of Medicine, China Medical University, Taichung, Taiwan

6 Department of Psychiatry, Taoyuan Psychiatric Center, Ministry of Health and Welfare, Taoyuan, Taiwan

7 Chinese Medicine Research Center, China Medical University, Taichung, Taiwan

Abstract

Objective(s): Parkinson’s disease (PD) is a common progressive neurodegeneration disease. Its incidence increases with age and affects about 1% of people over 60. Incidentally, transient receptor potential V1 (TRPV1) and its relation with neuroinflammation in mouse brain has been widely reported.
Materials and Methods: We used 6-hydroxydopamine (6-OHDA) to induce PDD in mice. We then used the Morris water maze and Bio-Plex to test learning and inflammatory mediators in mouse plasma. Western blotting and immunostaining were used to examine TRPV1 pathway in the hippocampus and medial prefrontal cortex (mPFC).
Results: On acquisition days 3 (Control = 4.40 ± 0.8 sec, PDD = 9.82 ± 1.52 sec, EA = 5.04 ± 0.58 sec, Riva = 4.75 ± 0.87 sec; P=0.001) and 4, reversal learning days 1, 2, 3 (Control = 2.86 ± 0.46 sec, PDD = 9.80 ± 1.83 sec, EA = 4.6 ± 0.82 sec, Riva = 4.6 ± 1.03 sec; P=0.001) and 4, PDD mice showed significantly longer escape latency than the other three groups. Results showed that several cytokines were up-regulated in PDD mice and reversed by EA and rivastigmine. TRPV1 and downstream molecules were up-regulated in PDD mice and further reversed by EA and rivastigmine. Interestingly, α7 nicotinic receptors and parvalbumin levels in both the hippocampus and prefrontal cortex increased in EA-treated mice, but not in rivastigmine-treated mice.
Conclusion: Our results showed that TRPV1 played a role in the modulation of neuroinflammation of PDD, and could potentially be a new target for treatment.

Keywords

References

1. Hely MA, Reid WG, Adena MA, Halliday GM, Morris JG. The Sydney multicenter study of Parkinson’s disease: the inevitability of dementia at 20 years. Mov Disord 2008; 23:837-844.
2. Litvan I, Aarsland D, Adler CH, Goldman JG, Kulisevsky J, Mollenhauer B, et al. MDS task force on mild cognitive impairment in Parkinson’s disease: critical review of PD-MCI. Mov Disord 2011; 26:1814-1824.
3. Kehagia AA, Barker RA, Robbins TW. Neuropsychological and clinical heterogeneity of cognitive impairment and dementia in patients with Parkinson’s disease. Lancet Neurol 2010; 9:1200-1213.
4. Diaz NL, Waters CH. Current strategies in the treatment of Parkinson’s disease and a personalized approach to management. Expert Rev Neurother 2009; 9:1781-1789.
5. Aarsland D, Creese B, Politis M, Chaudhuri KR, Ffytche DH, Weintraub D, et al. Cognitive decline in Parkinson disease. Nat Rev Neurol 2017; 13:217-231.
6. Zinger A, Barcia C, Herrero MT, Guillemin GJ. The involvement of neuroinflammation and kynurenine pathway in Parkinson’s disease. Parkinsons Dis 2011; 1-11.
7. Tan EK, Chao YX, West A, Chan LL, Poewe W, Jankovic J. Parkinson disease and the immune system - associations, mechanisms and therapeutics. Nat Rev Neurol 2020; 16:303-318.
8. Kong WL, Peng YY, Peng BW. Modulation of neuroinflammation: role and therapeutic potential of TRPV1 in the neuro-immune axis. Brain Behav Immun 2017; 64:354-366.
9. Luo L, Wang Y, Li B, Xu L, Kamau PM, Zheng J, et al. Molecular basis for heat desensitization of TRPV1 ion channels. Nat Commun 2019; 10:2134-2146.
10. Li M, Zhu M, Xu Q, Ding F, Tian Y, Zhang M. Sensation of TRPV1 via 5-hydroxytryptamine signaling modulates pain hypersensitivity in a 6-hydroxydopamine induced mice model of Parkinson’s disease. Biochem Biophys Res Commun 2020; 521:868-873.
11. Marrone MC, Morabito A, Giustizieri M, Chiurchiù V, Leuti A, Mattioli M, et al. TRPV1 channels are critical brain inflammation detectors and neuropathic pain biomarkers in mice. Nat Commun 2017; 8:15292-15310.
12. Thacker EL, O’Reilly EJ, Weisskopf MG, Chen H, Schwarzschild MA, McCullough ML, et al. Temporal relationship between cigarette smoking and risk of Parkinson disease. Neurology 2007; 68:764-768.
13. Mappin-Kasirer B, Pan H, Lewington S, Kizza J, Gray R, Clarke R, et al. Tobacco smoking and the risk of Parkinson disease: a 65-year follow-up of 30,000 male British doctors. Neurology 2020; 94:1-7.
14. Zhou FM, Wilson CJ, Dani JA. Cholinergic interneuron characteristics and nicotinic properties in the striatum. J Neurobiol 2002; 53:590-605.
15. Braak H, Müller CM, Rüb U, Ackermann H, Bratzke H, de Vos RA, et al. Pathology associated with sporadic Parkinson’s disease--where does it end? J Neural Transm Suppl 2006:89-97.
16. Pimlott SL, Piggott M, Owens J, Greally E, Court JA, Jaros E, et al. Nicotinic acetylcholine receptor distribution in Alzheimer’s disease, dementia with Lewy bodies, Parkinson’s disease, and vascular dementia: in vitro binding study using 5-[(125)i]-a-85380. Neuropsychopharmacology 2004; 29:108-116.
17. Nakano I, Hirano A. Parkinson’s disease: neuron loss in the nucleus basalis without concomitant Alzheimer’s disease. Ann Neurol 1984; 15:415-418.
18. Emre M, Aarsland D, Albanese A, Byrne EJ, Deuschl G, De Deyn PP, et al. Rivastigmine for dementia associated with Parkinson’s disease. N Engl J Med 2004; 351:2509-2518.
19. Oh YS, Kim JS, Lee PH. Effect of rivastigmine on behavioral and psychiatric symptoms of Parkinson’s disease dementia. J Mov Disord 2015; 8:98-102.
20. Liu Y, Zeng X, Hui Y, Zhu C, Wu J, Taylor DH, et al. Activation of α7 nicotinic acetylcholine receptors protects astrocytes against oxidative stress-induced apoptosis: implications for Parkinson’s disease. Neuropharmacology 2015; 91:87-96.
21. Foucault-Fruchard L, Antier D. Therapeutic potential of α7 nicotinic receptor agonists to regulate neuroinflammation in neurodegenerative diseases. Neural Regen Res 2017; 12:1418-1421.
22. Liao H-Y, Lin Y-W. Electroacupuncture reduces cold stress-induced pain through microglial inactivation and transient receptor potential V1 in mice. Chin Med 2021; 16:43-58.
23. Lee SH, Lim S. Clinical effectiveness of acupuncture on Parkinson disease: a PRISMA-compliant systematic review and meta-analysis. Medicine (Baltimore) 2017; 96:1-9.
24. Kim SR, Lee TY, Kim MS, Lee MC, Chung SJ. Use of complementary and alternative medicine by Korean patients with Parkinson’s disease. Clin Neurol Neurosurg 2009; 111:156-160.
25. Pecci C, Rivas MJ, Moretti CM, Raina G, Ramirez CZ, Díaz S, et al. Use of complementary and alternative therapies in outpatients with Parkinson’s disease in Argentina. Mov Disord 2010; 25:2094-2098.
26. Lökk J, Nilsson M. Frequency, type and factors associated with the use of complementary and alternative medicine in patients with Parkinson’s disease at a neurological outpatient clinic. Parkinsonism Relat Disord 2010; 16:540-544.
27. Tan LC, Lau PN, Jamora RD, Chan ES. Use of complementary therapies in patients with Parkinson’s disease in Singapore. Mov Disord 2006; 21:86-89.
28. Wei TH, Hsieh CL. Effect of acupuncture on the p38 Signaling pathway in several nervous system diseases: a systematic review. Int J Mol Sci 2020; 21:1-39.
29. Jang J-H, Yeom M-J, Ahn S, Oh J-Y, Ji S, Kim T-H, et al. Acupuncture inhibits neuroinflammation and gut microbial dysbiosis in a mouse model of Parkinson’s disease. Brain Behav Immun 2020; 89:641-655.
30. Lu KW, Yang J, Hsieh CL, Hsu YC, Lin YW. Electroacupuncture restores spatial learning and downregulates phosphorylated N-methyl-D-aspartate receptors in a mouse model of Parkinson’s disease. Acupunct Med 2017; 35:133-141.
31. Vorhees CV, Williams MT. Morris water maze: procedures for assessing spatial and related forms of learning and memory. Nat Protoc 2006; 1:848-858.
32. Lee Y, Lee S, Chang S-C, Lee J. Significant roles of neuroinflammation in Parkinson’s disease: therapeutic targets for PD prevention. Arch Pharm Res 2019; 42:416-425.
33. Ding SS, Hong SH, Wang C, Guo Y, Wang ZK, Xu Y. Acupuncture modulates the neuro–endocrine–immune network. QJM Int J Med 2013; 107:341-345.
34. Cools R, Barker RA, Sahakian BJ, Robbins TW. Mechanisms of cognitive set flexibility in Parkinson’s disease. Brain 2001; 124:2503-2512.
35. Murray AJ, Woloszynowska-Fraser MU, Ansel-Bollepalli L, Cole KLH, Foggetti A, Crouch B, et al. Parvalbumin-positive interneurons of the prefrontal cortex support working memory and cognitive flexibility. Sci Rep 2015; 5:16778-16792.
36. Caillard O, Moreno H, Schwaller B, Llano I, Celio MR, Marty A. Role of the calcium-binding protein parvalbumin in short-term synaptic plasticity. Proc Nati Acad Sci 2000; 97:13372-13377.
37. Nie J, Wei X, Xu X, Li N, Li Y, Zhao Y, et al. Electro-acupuncture alleviates adolescent cocaine exposure-enhanced anxiety-like behaviors in adult mice by attenuating the activities of PV interneurons in PrL. Faseb j 2020; 34:11913-11924.
38. Chao D, Shen X, Xia Y. From acupuncture to interaction between δ-opioid receptors and Na (+) channels: a potential pathway to inhibit epileptic hyperexcitability. Evid Based Complement Alternat Med 2013; 216016-216033.
39. Hurtado-Zavala JI, Ramachandran B, Ahmed S, Halder R, Bolleyer C, Awasthi A, et al. TRPV1 regulates excitatory innervation of OLM neurons in the hippocampus. Nat Commun 2017; 8:15878-15898.
40. Henderson EJ, Lord SR, Brodie MA, Gaunt DM, Lawrence AD, Close JCT, et al. Rivastigmine for gait stability in patients with Parkinson’s disease (ReSPonD): a randomised, double-blind, placebo-controlled, phase 2 trial. Lancet Neurol 2016; 15:249-258.
41. Rochester L, Hetherington V, Jones D, Nieuwboer A, Willems AM, Kwakkel G, et al. Attending to the task: interference effects of functional tasks on walking in Parkinson’s disease and the roles of cognition, depression, fatigue, and balance. Arch Phys Med Rehabil 2004; 85:1578-1585.
42. Reingold JL, Morgan JC, Sethi KD. Rivastigmine for the treatment of dementia associated with Parkinson’s disease. Neuropsychiatr Dis Treat 2007; 3:775-783.
43. Chen S, Bai L, Xu M, Wang F, Yin L, Peng X, et al. Multivariate granger causality analysis of acupuncture effects in mild cognitive impairment patients: an fMRI study. Evid Based Complement Alternat Med 2013; 127271-127283.
44. Abraham TS, Chen ML, Ma SX. TRPV1 expression in acupuncture points: response to electroacupuncture stimulation. J Chem Neuroanat 2011; 41:129-136.
45. Chen HC, Chen MY, Hsieh CL, Wu SY, Hsu HC, Lin YW. TRPV1 is a responding channel for acupuncture manipulation in mice peripheral and central nerve system. Cell Physiol Biochem 2018; 49:1813-1824.
46. Choowanthanapakorn M, Lu K-W, Yang J, Hsieh C-L, Lin Y-W. Targeting TRPV1 for body weight control using TRPV1−/− mice and electroacupuncture. Sci Rep 2015; 5:17366-17375.
47. Lin Y-W, Chou AIW, Su H, Su K-P. Transient receptor potential V1 (TRPV1) modulates the therapeutic effects for comorbidity of pain and depression: the common molecular implication for electroacupuncture and omega-3 polyunsaturated fatty acids. Brain Behav Immun 2020; 89:604-614.
48. Wu SY, Chen WH, Hsieh CL, Lin YW. Abundant expression and functional participation of TRPV1 at zusanli acupoint (ST36) in mice: mechanosensitive TRPV1 as an “acupuncture-responding channel”. BMC Complement Altern Med 2014; 14:96-111.
49. Lin J-G, Hsieh C-L, Lin Y-W. Analgesic effect of electroacupuncture in a mouse fibromyalgia model: Roles of TRPV1, TRPV4, and pERK. PLoS One 2015; 10:1-16.
50. Yen CM, Hsieh CL, Lin YW. Electroacupuncture reduces chronic fibromyalgia pain through attenuation of transient receptor potential vanilloid 1 signaling pathway in mouse brains. Iran J Basic Med Sci 2020; 23:894-900.
51. Chen W-H, Tzen JTC, Hsieh CL, Chen YH, Lin T-J, Chen S-Y, et al. Attenuation of TRPV1 and TRPV4 expression and function in mouse inflammatory pain models using electroacupuncture. Evid Based Complement Alternat Med 2012; 1-12.
52. Lu K-W, Hsu C-K, Hsieh C-L, Yang J, Lin Y-W. Probing the effects and mechanisms of electroacupuncture at ipsilateral or contralateral ST36–ST37 acupoints on CFA-induced inflammatory pain. Sci Rep 2016; 6:22123-22134.
53. Yang J, Hsieh C-L, Lin Y-W. Role of transient receptor potential vanilloid 1 in electroacupuncture analgesia on chronic inflammatory pain in mice. BioMed Res Int 2017; 1-8.
54. Liao H-Y, Hsieh C-L, Huang C-P, Lin Y-W. Electroacupuncture attenuates CFA-induced inflammatory pain by suppressing Nav1.8 through S100B, TRPV1, opioid, and adenosine pathways in mice. Sci Rep 2017; 7:42531-42544.
55. Yen CM, Wu TC, Hsieh CL, Huang YW, Lin YW. Distal electroacupuncture at the LI4 acupoint reduces CFA-induced inflammatory pain via the brain TRPV1 signaling pathway. Int J Mol Sci 2019; 20:1-13.
56. Hsu HC, Hsieh CL, Lee KT, Lin YW. Electroacupuncture reduces fibromyalgia pain by downregulating the TRPV1-pERK signalling pathway in the mouse brain. Acupunct Med 2020; 38:101-108.
57. Inprasit C, Lin YW. TRPV1 responses in the cerebellum lobules V, VIa and VII using electroacupuncture treatment for inflammatory hyperalgesia in murine model. Int J Mol Sci 2020; 21:1-16.
58. Inprasit C, Lin Y-W, Huang C-P, Wu S-Y, Hsieh C-L. Targeting TRPV1 to relieve motion sickness symptoms in mice by electroacupuncture and gene deletion. Sci Rep 2018; 8:10365-10375.
59. Guo ZL, Fu LW, Su HF, Tjen ALSC, Longhurst JC. Role of TRPV1 in acupuncture modulation of reflex excitatory cardiovascular responses. Am J Physiol Regul Integr Comp Physiol 2018; 314:1-12.
60. Wang S-J, Yang H-Y, Xu G-S. Acupuncture alleviates colorectal hypersensitivity and correlates with the regulatory mechanism of TrpV1 and p-ERK. Evid Based Complement Alternat Med 2012; 483123-483133.

Iranian Journal of Basic Medical Sciences
Volume 24, Issue 10
October 2021
Pages 1336-1345

Files

Share

How to cite

Statistics